Berruti A, Torta M, Piovesan A, Raucci C A, Orlandi F, Panero A, Dogliotti L, Angeli A
Department of Clinical and Biological Sciences, Internal Medicine and Medical Oncology, University of Torino at San Luigi, Gonzaga Hospital, Orbassano, Italy.
Anticancer Res. 1995 Nov-Dec;15(6B):2871-5.
A panel of bone turn-over markers was assessed in 75 normocalcemic patients bearing bone metastases from breast cancer (BC), and in 25 advanced/metastatic BC patients without clinical appearance of bone involvement. 115 healthy women, stratified in three subgroups according to age served as controls. Bone formation was investigated by measuring serum carboxyterminal propeptide of type I procollagen (PICP), Bone Gla Protein (BGP, osteocalcin), bone isoenzyme of alkaline phosphatase (BALP); bone resorption by measuring serum carboxyterminal telopeptide of type I collagen (ICTP), fasting urinary hydroxyproline/creatinine (OHPro/Cr) and calcium/creatinine (Ca/Cr). In patients with bone metastases the percent of supranormal values (higher than mean plus 2 SD of the age-matched controls) ranged between 25% and 40% for indices of bone formation, about 73% for both ICTP and OHPro/Cr and about 30% for Ca/Cr. The median levels of all bone turn-over markers were higher in bone metastatic patients than in those without apparent skeletal involvement, but significance was attained only for OHPro/Cr, Ca/Cr and BALP. Supranormal levels of ICTP and OHPro/Cr were also found in about 65-70% of patients without apparent skeletal involvement. ICTP and Ca/Cr significantly correlated with bone pain score, BALP, ICTP, Ca/Cr significantly correlated with the number of tumour appearances in bone. In conclusion, the bone resorption indices, ICTP and OHPro/Cr, are much more frequently elevated than bone formation indices in BC patients with or without skeletal involvement. Their potential use in the early detection of bone metastases is hampered by the insufficient knowledge on specificity. Among the biochemical markers evaluated, Ca/Cr, ICTP and BALP, due to correlation with clinical aspects, appear the most interesting for follow-up studies.
对75例患有乳腺癌(BC)骨转移的血钙正常患者以及25例无骨受累临床表现的晚期/转移性BC患者进行了一组骨转换标志物评估。115名健康女性根据年龄分为三个亚组作为对照。通过测量血清I型前胶原羧基末端前肽(PICP)、骨钙素(BGP,骨钙素)、碱性磷酸酶骨同工酶(BALP)来研究骨形成;通过测量血清I型胶原羧基末端肽(ICTP)、空腹尿羟脯氨酸/肌酐(OHPro/Cr)和钙/肌酐(Ca/Cr)来研究骨吸收。在骨转移患者中,骨形成指标的超常值百分比(高于年龄匹配对照组平均值加2个标准差)在25%至40%之间,ICTP和OHPro/Cr约为73%,Ca/Cr约为30%。所有骨转换标志物的中位数水平在骨转移患者中高于无明显骨骼受累的患者,但仅OHPro/Cr、Ca/Cr和BALP具有统计学意义。在约65 - 70%无明显骨骼受累的患者中也发现了ICTP和OHPro/Cr的超常水平。ICTP和Ca/Cr与骨痛评分显著相关,BALP、ICTP、Ca/Cr与骨肿瘤出现数量显著相关。总之,无论有无骨骼受累,BC患者的骨吸收指标ICTP和OHPro/Cr升高的频率远高于骨形成指标。它们在骨转移早期检测中的潜在应用因特异性知识不足而受到阻碍。在所评估的生化标志物中,Ca/Cr、ICTP和BALP由于与临床情况相关,似乎是随访研究中最有意义的。